Individuals with gallbladder disease or history of gallstones should be monitored, as rapid weight loss can precipitate gallstone formation
In large obesity trials using full doses, once-weekly semaglutide and tirzepatide led to substantial average weight loss and improved metabolic markers in adults with obesity.[13] For example, the STEP 1 trial of once-weekly semaglutide in adults with overweight or obesity and the SURMOUNT-1 tirzepatide obesity trial both showed strong weight-loss effects when combined with lifestyle changes
However, as of now, the FDA has approved GLP-1 drugs only in the form of injections and pills 1 , 2 , and there are no approved form of GLP-1 transdermal (skin) patches which are in medical use
Taking the injection on a full stomach, staying hydrated and eating smaller, more frequent meals can help manage nausea, notes Jennifer Habashy, NMD, MS, assistant medical director at Claya